London
· Delayed Price · Currency is GBP · Price in USD Ultragenyx Pharmaceutical Statistics
Total Valuation
Ultragenyx Pharmaceutical has a market cap or net worth of GBP 3.22 billion. The enterprise value is 3.31 billion.
| Market Cap | 3.22B |
| Enterprise Value | 3.31B |
Important Dates
The next estimated earnings date is Monday, February 10, 2025.
| Earnings Date | Feb 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +22.79% |
| Shares Change (QoQ) | +10.30% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 89.10M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 31.36 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.93 |
| EV / Sales | 7.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.38 |
Financial Position
The company has a current ratio of 2.81, with a Debt / Equity ratio of 2.58.
| Current Ratio | 2.81 |
| Quick Ratio | 2.47 |
| Debt / Equity | 2.58 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.14 |
| Interest Coverage | -8.26 |
Financial Efficiency
Return on equity (ROE) is -289.98% and return on invested capital (ROIC) is -29.76%.
| Return on Equity (ROE) | -289.98% |
| Return on Assets (ROA) | -24.12% |
| Return on Capital (ROIC) | -29.76% |
| Revenue Per Employee | 305,658 |
| Profits Per Employee | -326,850 |
| Employee Count | 1,276 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 19.17 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.09% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -8.09% |
| 50-Day Moving Average | 45.28 |
| 200-Day Moving Average | 47.40 |
| Relative Strength Index (RSI) | 44.73 |
| Average Volume (20 Days) | 386 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.53 |
Income Statement
In the last 12 months, Ultragenyx Pharmaceutical had revenue of GBP 390.02 million and -417.06 million in losses. Loss per share was -4.80.
| Revenue | 390.02M |
| Gross Profit | -147.42M |
| Operating Income | -399.72M |
| Pretax Income | -418.62M |
| Net Income | -417.06M |
| EBITDA | -373.84M |
| EBIT | -399.72M |
| Loss Per Share | -4.80 |
Balance Sheet
The company has 453.26 million in cash and 680.81 million in debt, giving a net cash position of -76.03 million.
| Cash & Cash Equivalents | 453.26M |
| Total Debt | 680.81M |
| Net Cash | -76.03M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 263.99M |
| Book Value Per Share | 2.81 |
| Working Capital | 383.94M |
Cash Flow
In the last 12 months, operating cash flow was -312.31 million and capital expenditures -6.29 million, giving a free cash flow of -318.60 million.
| Operating Cash Flow | -312.31M |
| Capital Expenditures | -6.29M |
| Free Cash Flow | -318.60M |
| FCF Per Share | n/a |
Margins
Gross margin is -37.80%, with operating and profit margins of -102.49% and -106.93%.
| Gross Margin | -37.80% |
| Operating Margin | -102.49% |
| Pretax Margin | -107.33% |
| Profit Margin | -106.93% |
| EBITDA Margin | -95.85% |
| EBIT Margin | -102.49% |
| FCF Margin | n/a |
Dividends & Yields
Ultragenyx Pharmaceutical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.79% |
| Shareholder Yield | -22.79% |
| Earnings Yield | -12.96% |
| FCF Yield | -9.90% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ultragenyx Pharmaceutical has an Altman Z-Score of -1.96. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.96 |
| Piotroski F-Score | n/a |